SUBSCRIBE
SUBSCRIBE
News   Drug Development

Geron Corporation Initiates Clinical Trial of GRN163L in Combination with Paclitaxel and Bevacizumab in Patients with Breast Cancer

August 7, 2008 | 
1 min read

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer.

Clinical research Phase I
MORE ON THIS TOPIC
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pop art Medicine pill or tablet icon isolated on color background. Capsule pill and drug sign. Pharmacy design. Vector Illustration
Pain
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
March 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky